Annuncio pubblicitario
Italia markets close in 3 hours 35 minutes

  • FTSE MIB

    33.703,51
    +394,74 (+1,19%)
     

  • Dow Jones

    39.150,33
    +15,53 (+0,04%)
     

  • Nasdaq

    17.689,36
    -32,24 (-0,18%)
     

  • Nikkei 225

    38.804,65
    +208,18 (+0,54%)
     

  • Petrolio

    81,08
    +0,35 (+0,43%)
     

  • Bitcoin EUR

    57.055,45
    -2.850,86 (-4,76%)
     

  • CMC Crypto 200

    1.260,17
    -49,55 (-3,78%)
     

  • Oro

    2.339,60
    +8,40 (+0,36%)
     

  • EUR/USD

    1,0733
    +0,0036 (+0,33%)
     

  • S&P 500

    5.464,62
    -8,55 (-0,16%)
     

  • HANG SENG

    18.027,71
    -0,81 (-0,00%)
     

  • Euro Stoxx 50

    4.947,10
    +39,80 (+0,81%)
     

  • EUR/GBP

    0,8473
    +0,0018 (+0,21%)
     

  • EUR/CHF

    0,9580
    +0,0028 (+0,29%)
     

  • EUR/CAD

    1,4677
    +0,0036 (+0,25%)
     

Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference

Solid Biosciences Inc.
·1 minuto per la lettura
Solid Biosciences Inc.
Solid Biosciences Inc.

CHARLESTOWN, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Citi 18th Annual BioPharma Conference on Thursday, September 7, 2023, at 9:40 AM ET.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.

Institutional investors interested in meeting with management during the conference may reach out to their Citi representative.

ANNUNCIO PUBBLICITARIO

About Solid Biosciences

Solid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne), AVB-401 a gene therapy program for the treatment of BAG3 mediated dilated cardiomyopathy, AVB-202-TT, a gene therapy program for the treatment of Friedreich’s Ataxia, and additional assets for the treatment of undisclosed fatal cardiac diseases. Solid aims to be the center of excellence across a given disease spectrum bringing together those with expertise in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Leah Monteiro
VP, Investor Relations & Communications
617-821-4427
lmonteiro@solidbio.com